Fissured tongue

Summary

Fissured tongue (MONDO:0007655) is a disease and 12 clinical trials. Top therapeutic interventions include doxycycline anhydrous, amoxicillin, and cefuroxime axetil. A subtype of tongue disorder — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Clinical trials: 12

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	fissured tongue
Mondo ID	MONDO:0007655
MeSH	D014063
OMIM	137400
DOID	DOID:11514
ICD-10-CM	K14.5
ICD-11	699700094
SNOMED CT	52368004
UMLS	C4540616
MedGen	1624209
Is cancer (heuristic)	no

Also known as: congenital fissure of tongue · congenital plicated tongue · ectopic geographic tongue · erythema migrans · fissure of tongue, congenital · Furrowed tongue · plicated tongue · scrotal tongue

Disease family

This is a subtype of tongue disorder. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › mouth disorder › tongue disorder › fissured tongue

Related subtypes (8): hypertrophy of tongue papillae, glossitis, hairy tongue, ankyloglossia, isolated congenital hypoglossia/aglossia, digestive duplication cyst of the tongue, tongue neoplasm, glossodynia

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 12.

Phase distribution (across all retrieved trials)

Phase	Trials
Not specified	9
PHASE4	2
PHASE3	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT01368341	PHASE4	COMPLETED	Comparing 3 Antibiotic Regimes for Erythema Migrans in General Practice
NCT01518192	PHASE4	COMPLETED	Comparison of Doxycycline and Cefuroxime Axetil for Treatment of Erythema Migrans: Clinical and Microbiological Outcome
NCT03966014	PHASE3	RECRUITING	Different Amoxicillin Treatment Regimens in Erythema Migrans Patients
NCT03462329	Not specified	RECRUITING	Patient’s Pretreatment Expectations About Post-Lyme Symptoms
NCT00132327	Not specified	COMPLETED	Analysis of Lyme Disease Lesions
NCT02145754	Not specified	COMPLETED	Culture Media for Borrelia Burgdorferi Sensu Lato
NCT02147249	Not specified	UNKNOWN	Cytokines and Chemokines in Erythema Migrans
NCT02414789	Not specified	COMPLETED	Lyme Borreliosis and Early Cutaneous Diagnostic
NCT03371563	Not specified	COMPLETED	Erythema Migrans in Elderly
NCT03505879	Not specified	COMPLETED	Next Generation Sequencing Detection of Lyme Disease
NCT03956212	Not specified	COMPLETED	Inflammatory Mediators in Erythema Migrans
NCT03980015	Not specified	COMPLETED	Inflammatory Responses in Solitary and Multiple Erythema Migrans

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
DOXYCYCLINE ANHYDROUS	4	6
AMOXICILLIN	4	1
CEFUROXIME AXETIL	4	1
PENICILLIN V	4	1
17	0	1